



News Release

PIVOTAL THERAPEUTICS ANNOUNCES SENIOR MANAGEMENT CHANGE

FOR IMMEDIATE RELEASE

November 14, 2014

Woodbridge, Ontario, November 14, 2014 - Pivotal Therapeutics Inc. (OTCQX:PVTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that Prakash Gowd has left as CFO to pursue new opportunities. "We would like to thank Prakash for his contributions and wish him well in his future endeavours," said Eugene Bortoluzzi, CEO, who has re-assumed the CFO role in addition to his CEO responsibilities.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product **VASCAZEN**[®] is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. **OMAZEN**[®] is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. **OMAZEN**[®] is a patented product available for sale and distribution in Canada. For more information about Pivotal visit www.pivotaltherapeutics.us.

Disclosure Notice

The information contained in this document is as of November 14, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

- # -

Company Contacts:

Kristine DiMatteo
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

Investor & Media Contact:

Stephen Kilmer
President, Kilmer Lucas Inc.
Phone: 647-872-4849
E-Mail: stephen@kilmerlucas.com